Feasibility & Study Assessment for Oncology Clinical Trials in EAEU
We evaluate the feasibility of conducting oncology and hematology clinical trials in Russia and CIS, including clinical site availability, patient recruitment potential, and regulatory pathway assessment.
Request feasibility assessment
What we assess
We provide a structured evaluation of your clinical trial before initiation:
- Protocol feasibility in EAEU region
- Availability of oncology and hematology clinical sites
- Patient population and recruitment potential
- Regulatory pathway via Ministry of Health (Russia / EAEU)
- Expected timelines for study start-up
- Operational risks and constraints
When this is relevant
This assessment is intended for sponsors who are:
- Planning oncology or hematology clinical trials in EAEU
- Expanding clinical development programs to Eastern Europe
- Evaluating patient recruitment feasibility in new geographies
- Preparing regulatory submission strategy for Russia/CIS
- Assessing operational viability of early-stage protocols
How we work
- Protocol review
Initial analysis of study design and requirements - Site mapping
Identification of suitable clinical oncology and hematology centers - Feasibility evaluation
Assessment of recruitment capacity and operational constraints - Regulatory pathway review
Overview of submission requirements and timelines - Structured feedback report
Clear recommendation on study viability and next steps - Optional execution proposal
If feasible — transition into full study setup and execution
Our role
We act as a local operator for clinical trials in the EAEU region, supporting sponsors with operational execution, regulatory interaction, and clinical site coordination.
Our focus is oncology, with strong expertise in hematology studies and collaboration with both regional and federal clinical centers.
What you receive
- Clear feasibility conclusion (go / no-go / conditional)
- Site availability overview
- Recruitment potential estimation
- Regulatory pathway outline
- Risk identification and mitigation points
- Recommended next steps for study activation
Turnaround time
Feasibility assessment is typically initiated within a short timeframe after protocol review and information submission.
